Daryl Murry

Daryl Murry

  • Associate Professor, Department of Pharmaceutical Sciences and Experimental Therapeutics / Division of Pharmaceutics and Translational Therapeutics

Office

5425 PHAR

Phone

(319) 335-8157

Research Narrative

His research interests include: incorporation of innovative dosing strategies into Phase I clinical trials, the development and validation of surrogate endpoints in clinical trials, and the clinical pharmacology of anti-neoplastic agents. Dr. Murry collaborates with a number of research groups within the Schools of Pharmacy, Medicine, and Public Health and with national partners across the country. Dr. Murry has published extensively in many health sciences journals. He is a member of the Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee and of the Holden Comprehensive Cancer Center.

Dr. Murry is currently an Associate Professor in the College of Pharmacy. Dr. Murry earned his BS and his PharmD degree from the University of Iowa College of Pharmacy. He completed his Residency training at the University of Iowa Hospitals and Clinics and his research fellowship training in cancer pharmacology at St. Jude Children's Research Hospital in Memphis. He then became co-director of the Clinical Pharmacology Unit at Baylor College of Medicine and Texas Children’s Hospital in Houston, Texas. Murry returned to the Midwest in 1998 to accept a position at Purdue University prior to arriving at the University of Iowa in 2003.

Curriculum vitae

Education
Pharmacokinetic Fellowship, St. Jude Children's Research Hospital, Memphis, Tennessee, 1991-1994.
Doctor of Pharmacy, University of Iowa, Iowa City, Iowa, 1989-1991.
ASHP Accredited Residency, University of Iowa Hospitals and Clinics, Iowa City, Iowa, 1987-1988.
Bachelor of Science, Pharmacy, University of Iowa, Iowa City, Iowa, 1983 -1987.

Professional Experience
Member, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, 2003–present.
Associate Professor, Clinical and Administrative Pharmacy, University of Iowa, Iowa City, Iowa, 2003–present.
Associate Professor, Department of Pharmacy Practice, Purdue University, West Lafayette, Indiana, 2001–2003.
Adjunct Assistant Professor, Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana, 2000–2001.
Assistant Professor, Department of Pharmacy Practice, Purdue University, Indianapolis, Indiana, 1998–2001.
Adjunct Assistant Professor, Department of Medicine, Indiana University, Indianapolis, Indiana, 1998–2003.
Assistant Professor, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 1994-1998.
Co-Director, Clinical Pharmacology Group, Baylor College of Medicine and Texas Children’s Cancer Center, Houston, Texas, 1994-1998.
Instructor, Department of Clinical Pharmacy, University of Tennessee, Memphis, Tennessee, 1991-1994.
Clinical Pharmacist, Pharmacy Department, University of Iowa Hospitals and Clinics, Iowa City, Iowa 1988-1991.

Honors and Awards
Hoechst-Rousel Excellence in Clinical Pharmacy, 1991.
Upjohn Research Award for Iowa Pharmacists, 1989.

Organizational Memberships
Recreation Services Committee 2004-present.
Graduate Review Committee, 2004.
CALGB PET Committee, 2003-present.
Curriculum Committee, University of Iowa College of Pharmacy, 2003-present.
Holden Cancer Center’s Protocol Review and Monitoring Committee, 2003-present.
Teaching Assistant Task Force, University of Iowa College of Pharmacy, 2003-2004.
Ph.D. Task Force, University of Iowa College of Pharmacy, 2003-2004.
Promotional Committee, University of Iowa College of Pharmacy, 2003-present.
Anesthesiologist Search Committee, Department of Veterinary Clinical Sciences, 2001.
Grievance Committee, Purdue University, 1999-2001.
Jenkins-Knevel Selection Committee, Purdue University,1999-2001.
PRF Grant Review Committee, Department of Pharmacy Practice, 1999-2000.
Search Committee, Walther Cancer Center, Purdue University, 1999-2000.
Sub-Committee on Graduate Applicant Review and Recruitment, Department of Pharmacy Practice, 1999-2000.
Graduate Committee, Purdue University, Department of Pharmacy Practice, 1999-2001.
American College of Clinical Pharmacy
American Society for Clinical Oncology
American Society for Clinical Pharmacology and Therapeutics
CALGB

Select Scholarly Activities
Phan H, Yoshizuka K, Murry D. Drug testing in the workplace. Pharmacotherapy, 32(7), 649-656, 2012.

Ince I, de Wildt SN, Peeters MY, Murry DJ, Tibboel D, Danhof M, Knibbe CA. Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Ther Drug Monit. 34(4):381-9, 2012.

Zhang H, Schmidt M, Murry DJ, Donovan MD. Permeation and systemic absorption of R- and S-baclofen across the nasal mucosa. J Pharm Sci. 100(7):2717-23, 2011.

Suneja M, Murry DJ, Stokes JB, Lim VS. Hormonal regulation of energy-protein homeostasis in hemodialysis patients: an anorexigenic profile that may predispose to adverse cardiovascular outcomes. Am J Physiol Endocrinol Metab. 300(1):E55-64, 2011.

de Wildt SN, Kearns GL, Murry DJ, Koren G, van den Anker JN. Ontogeny of midazolam glucuronidation in preterm infants. Eur J Clin Pharmacol. 66(2):165-70, 2010.

Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem. 19;285(8):5385-91, 2010.

Rodionov RN, Dayoub H, Lynch CM, Wilson KM, Stevens JW, Murry DJ, Kimoto M, Arning E, Bottiglieri T, Cooke JP, Baumbach GL, Faraci FM, Lentz SR. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Circ Res. 19;106(3):551-8, 2010.

Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 27(11):1800-5, 2009.

Chiorean EG, Porter JM, Foster AE, Al Omari AS, Yoder CA, Fife KL, Strother RM, Murry DJ, Yu M, Jones DR, Sweeney CJ. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naïve malignancies. Clin Cancer Res. 14(4):1131-7, 2008.

Sandlund JT, Santana VM, Hudson MM, Onciu M, Head D, Murry DJ, Ribeiro R, Wallace D, Rencher R, Pui CH. Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood. Cancer. 113(4):782-90, 2008.

Dayal S, Rodionov RN, Arning E, Bottiglieri T, Kimoto M, Murry DJ, Cooke JP, Faraci FM, Lentz SR. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol. 295(2):H816-25, 2008.

Huang RS, Murry DJ, Foster DR. Role of xenobiotic efflux transporters in resistance to vincristine. Biomed Pharmacother. 62(2):59-64, 2008.

Murry DJ, Omari A. Pharmacogenetics of the cytochrome p450 enzyme system: review of current knowledge and clinical significance. J Pharmacy Practice, 20: 206-219, 2007.

Schneider B, Fukunaga A, Murry D, Yoder C, Fife K, Foster A, Rosenberg L, Kelich S, Li L, Sweeney C. A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors. Cancer Chemother Pharmacol. 59(2):261-8, 2007.

Xing D, Murry DJ, Schmidt MS, Hohl RJ, Martins JB. Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity. Heart Rhythm. 4(5):629-37, 2007.

Naik H, Wei SY, Schmidt MS, Murry DJ, Fleckenstein L. Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human urine. J Chromatogr B Analyt Technol Biomed Life Sci. 853(1-2):80-7, 2007.

Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, Camitta BM, Dreyer ZE, Bomgaars LR. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 59(6):847-53, 2007.

James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs. 25(1):41-8, 2007.

Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 25(21):3055-60, 2007.

 Naik H, Imming P, Schmidt MS, Murry DJ, Fleckenstein L. Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human blood for application to clinical pharmacokinetic studies. J Pharm Biomed Anal. 45(1):112-9, 2007.

Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry DJ, Krull JH, Fife K, Battiato L, Cleverly A, Chaudhary AK, Chaudhuri T, Sandler A, Mita AC, Rowinsky EK.Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.  Clin Cancer Res. 12(2):536-42, 2006.

Schmidt MS, Huang R, Classon RJ, Murry DJ.  Determination of vincristine in infant plasma by liquid chromatography-atmospheric pressure chemical ionization-mass spectroscopy.  J Pharm Biomed Anal. 41(2):540-3, 2006.

Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR.  Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines.  Biochem Pharmacol. 71(12):1695-704, 2006.

Miller AA, Al Omari A, Murry DJ, Case D.  Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.  Lung Cancer. 54(3):379-85, 2006.

Naik H, Murry DJ, Kirsch LE, Fleckenstein L. Development and validation of a high-performance liquid chromatography-mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 816(1-2):233-42, 2005.

Schmidt MS, Prisinzano TE, Tidgewell K, Harding W, Butelman ER, Kreek MJ, Murry DJ. Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci. 818(2):221-5, 2005.

Quinney SK, Sanghani SP, Davis WI, Hurley TD, Sun Z, Murry DJ, Bosron WF. Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther. 313(3):1011-6, 2005.

Sweeney CJ, Mehrotra S, Sadaria MR, Kumar S, Shortle NH, Roman Y, Sheridan C, Campbell RA, Murry DJ, Badve S, Nakshatri H. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther. 4(6):1004-12, 2005.

Tidgewell, W.W. Harding, M.S. Schmidt, K.G. Holden, Murry DJ, and T.E. Prisinzano. A Facile Method for the Preparation of Deuterium Labeled Salvinorin A: Synthesis of [2,2,2-2H3]-Salvinorin A. Bioorganic and Medicinal Chem. Lett., 14, 5099, 2004.

EA Curry, Murry DJ, C Yoder, K Fife, V Armstrong, H Nakshatri M O’Connell CJ Sweeney.  Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer.  Investigational New Drugs 22: 299-305, 2004.

KD Miller, SE Soule, TG Haney, P Guiney, Murry DJ, L Lenaz, SL Sun, GW Sledge.  A Phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer.  Investigational New Drugs 22: 69-73, 2004.

MR Hemm, SD Rider, J Ogas, Murry DJ, C Chapple.  Light induces phenylpropanoid metabolism in Arabidopsis roots.  The Plant Journal 38: 765-778, 2004.

AK Fukunaga, S  Marsh, Murry DJ, TD Hurley HL Mcleod.  Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.  The Pharmacogenomics Journal 4(5):307-14, 2004.

Z Sun, Murry DJ, SP Sanghani WI Davis NY Kedishvili, Q Zou, TD Hurley, WF Bosron.  Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1.  J Pharmacol Exp Ther. 310(2) 469-76, 2004.

Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF.  Hydrolysis of irinotecan and its oxidative metabolites, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.  Drug Metabolism and Disposition, 32:505-511, 2004.

Boria PA, Murry DJ, Bennett P, Glickman NW, Snyder PW, Merkel BL, Schlittler D, Mutsaers AJ, Thomas R, Bonney P, Knapp DW. Phase I/II clinical trial of cisplatin/piroxicam in canine oral cancer. J Amer Vet Med Assoc, 224:1-7, 2004.

Sanghani S.P., Quinney S.K., Fredenburg T.B., Sun Z, Davis, W.I., Murry DJ, Cummings, O.W., Seitz, D.E., Bosron, W.F.  Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Cancer Research 9:4983-4991, 2003.

Thompson, P., Balis, F., Serabe, B.M., Berg, S., Adamson, P., Klenke, R., Aiken, A., Packer, R., Murry DJ, Jakacki, R., Blaney S.M.  Pharmacokinetics of Phenylacetate administered as a 30 minute infusion in children with refractory cancer. Cancer Chemother Pharmacol 52:417-423, 2003.

de Wildt S.N., Kearns, G.L., Hop W.C.J., Murry DJ, Abdel-Rahman S.M., van den Anker J.N. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 53:390-392, 2002.

Murry DJ, Cherrick I, Salama V., Berg S., Bernstein M., Kuttesch N., Blaney S.M. Influence of Phenytoin on the Disposition of Irinotecan. Journal of Pediatric Hematology/Oncology 24:130-133, 2002.

de Wildt S.N., Kearns, G.L., Hop W.C.J., Murry DJ, Abdel-Rahman S.M., van den Anker J.N. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clinical Pharmacology and Therapeutics 70:525-530, 2001.

Goldstein, S.L., Murry DJ, May S., Aleksic A., Sowinski, K.M. Blaney S. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. Ped Neph 16:1015-8, 2001.

Liang, H., Scott, M.K., Murry DJ, Sowinski, K.M.  Determination of albumin and myoglobin in dialysate and ultrafiltrate samples by high-performance size exclusion chromatography.   Journal of Chromatography B, 754:141-151, 2001.

Murry DJ, Blaney, S.M.  Clinical pharmacology of encaspulated sustained-release cytarabine.  Annals of Pharmacotherapy, 34:1173-1178,  2000.
Fausel, C.L., Murry DJ,  Hematologic malignancies.  Pharmacotherapy Self-Assessment Program, 3rd Edition, 2000.

Research interests
Clinical Pharmacology of Feverfew in Prostate Cancer.  Role: Co-Investigator.  The study is designed to evaluate the influence of parthenolide on NF-KB.  Status: Open for enrollment.

Influence of Interferon on Taxol Metabolism.  Role: Co-Investigator.  The study is designed to evaluate the influence of prolonged interferon therapy on taxol metabolism.  Status: Open for enrollment.

Folate Status, Purine and Pyrimindine Metabolism in Children with Down Syndrome.  Role: Principal Investigator.  This study will evaluate toxicity to antifolate drugs experienced by Down syndrome patients being treated for childhood cancer.  Study closed, data analysis ongoing.

Folate metabolism in children with Down syndrome.  Role: Principal Investigator.  This study will evaluate folate metabolism in children with and without Down syndrome. Study closed, data analysis ongoing.

A trial of irinotecan in children with solid tumors.  Role: Co-Investigator responsible for the pharmacology studies in this phase I trial. Study closed, data analysis ongoing.

Evaluation of three methods to determine glomerular filtration rate in children.  Role: Co-Investigator.  The study is designed to assess the agreement between three tests used to determine glomerular filtration rate in children. Study closed, data analysis ongoing.